Biotricity
Biotricity is a Nasdaq-listed medical technology company that develops FDA-cleared remote cardiac monitoring devices — including Bioflux, Biocore Pro, Bioheart, and Biokit — and the Biocare cloud platform for cardiac diagnostics, remote patient monitoring, and chronic care management serving physicians, cardiology clinics, and consumers.
- Company typePublic
- Founded2015
- HeadquartersRedwood City, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Biotricity does
Biotricity Inc. (NASDAQ: BTCY) is a medical technology company headquartered in Redwood City, California, that develops FDA-cleared remote cardiac monitoring hardware and an integrated cloud-based disease management platform. Founded in 2014–2015 by Dr. Waqaas Al-Siddiq and listed on Nasdaq in 2021, the company targets two distinct end markets: clinical cardiology (via physician-prescribed devices reimbursable under RPM and Holter CPT codes) and consumer health (via direct-to-consumer e-commerce). Its core product portfolio spans Bioflux (cellular cardiac outpatient telemetry), Biocore and Biocore Pro (3-lead wireless cardiac monitors — the latter with a built-in SIM card), Bioheart (personal 24/7 heart rhythm monitoring), Biokit (multi-vital RPM kit with blood pressure cuff, pulse oximeter, and thermometer), and the Biocare software platform that unifies diagnostics, remote patient monitoring, telemedicine, and chronic care management.
The Biocare platform functions as the technical backbone across the portfolio: continuous ECG streams from Biotricity devices are analyzed using AI-driven anomaly detection, transmitted automatically via cellular or Bluetooth, and surfaced to physicians through a diagnostic portal with automated reporting and threshold-based alerts. The Biocore Pro is described as the only 3-channel cardiac monitor with integrated cellular data transfer, and devices such as Biocore support up to 30 days of recording with daily recharging. Hardware is supported by 15 issued patents and 14 pending applications covering 3-lead ECG architectures, cellular connectivity, and a versatile multi-sensor patch/watch form factor.
Biotricity generates revenue from four streams: hardware/device sales (Bioflux, Biocore, Biocore Pro, Bioheart, Biokit), recurring subscription revenue from the Biocare platform, insurance-reimbursable RPM services billed by clinics, and one-time consumer service fees (notably the HeartSecure 10-day program at $149–$199). The company distributes through physician/clinic direct sales (over 2,500 healthcare professionals using Biocore), the Biodirect direct-to-patient shipping program, healthcare provider networks, and its own e-commerce storefronts. As of Q3 FY2026, quarterly revenue was $3.99 million, with 9-month FY2025 revenue of $11.7 million (up 16% year-over-year); however, the company carries an accumulated deficit of $142.1 million and a working capital deficiency of $18.8 million, signaling that growth has not yet translated to profitability.
Biotricity firmographics
Firmographics- Name
- Biotricity
- Legal name
- Biotricity Inc.
- Website
- https://biotricity.com
- Company type
- Public
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Biotricity is a Nasdaq-listed medical technology company that develops FDA-cleared remote cardiac monitoring devices — including Bioflux, Biocore Pro, Bioheart, and Biokit — and the Biocare cloud platform for cardiac diagnostics, remote patient monitoring, and chronic care management serving physicians, cardiology clinics, and consumers.
- Ownership category
- akta.pro rank
Biotricity industry classification
Industry- Product category
- Remote cardiac monitoring devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders) (HLAHACAB)
- akta.pro secondary industries
- Connected Medical Devices & Wearables (Sensors, Patches, Implantables) (HLACAPAB), Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration) (HLACAPAI), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA), ECG/EKG & Heart Rhythm Monitors (Consumer) (CRACAQAC)
Keywords
Where Biotricity is headquartered
LocationHeadquarters
- HQ city
- Redwood City
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Biotricity business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
Revenue model
- Device/Hardware Sales: Sale of FDA-cleared cardiac monitoring devices including Biocore, Biocore Pro, Bioheart, and Biokit to healthcare providers and consumers.
- Subscription/Recurring Revenue: Recurring revenue from subscription services including cloud data storage, diagnostic analysis, and platform access fees for healthcare providers using Biocare.
- Insurance Reimbursement: Healthcare providers can bill insurance for remote patient monitoring services using Biotricity devices. Biocore Pro enables physician-enabled billing where clinic revenue from claims is paid directly to the clinic, not the device vendor.
- HeartSecure Program: One-time cardiac monitoring service at $149-$199 for 10-day comprehensive heart analysis including device rental, cardiologist review, and detailed report delivery.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Pay-as-you-go | HeartSecure - 10-Day At-Home Cardiac Monitoring |
| Other | Multi-year contract | Biocore/Biocore Pro - Physician Prescribed |
| Subscription | Monthly | Bioheart - Consumer Direct |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Biotricity product offering
Product offeringCore offering
Biotricity designs, manufactures, and sells FDA-cleared remote cardiac monitoring hardware — including Bioflux, Biocore, Biocore Pro, Bioheart, and Biokit — that capture continuous ECG and vital-sign data via built-in cellular and Bluetooth connectivity and feed it to physicians through the proprietary Biocare cloud platform. Its offerings support arrhythmia detection, Holter monitoring, remote patient monitoring, chronic cardiac disease management, and direct-to-consumer at-home heart analysis (HeartSecure) for both clinical and personal use.
Product overview
Biotricity offers a comprehensive suite of remote cardiac monitoring solutions for medical and consumer markets. The portfolio consists of five core hardware products integrated through the Biocare software platform: Bioflux (FDA-cleared cardiac outpatient monitoring device with cellular technology), Biocore and Biocore Pro (3-lead wireless cardiac monitors with Bluetooth/cellular connectivity), Bioheart (personal 24/7 heart rhythm monitoring for individuals), and Biokit (remote patient monitoring kit with vitals measurement tools). These devices integrate with the Biocare disease management platform which provides chronic care management, telemedicine, and bi-directional communication. The company also offers HeartSecure, an at-home cardiac monitoring service. The products are designed to work together to provide a holistic approach to cardiac diagnostics, remote patient monitoring, and chronic disease management.
Differentiator
Problem solved
Functional benefit
Brands
- Bioflux: Single-unit cardiac outpatient monitoring (COM) device for physicians
- Biocore Pro
- Bioheart
- Biokit
- Biocare
- HeartSecure
Products and services
- Bioflux FDA-cleared cardiac outpatient monitoring (COM) device that captures ECG data wirelessly through cellular technology, continuously analyzes it for anomalies, and automatically transmits data for physician review. Intended for healthcare providers diagnosing cardiac events in outpatient settings.
- Biocore 3-lead wireless cardiac monitor in a compact patch form with Bluetooth connectivity, supporting up to 30 days of recording with automated data offloading and results delivered in 3-5 days (compared to 2 weeks for traditional Holter monitors). FDA-cleared, prescription-only device for cardiologists and clinics conducting arrhythmia and Holter monitoring.
- Biocore Pro World's only 3-channel cardiac monitor with built-in SIM card for cellular connectivity, enabling automated data transfer without manual downloads via Bluetooth and cellular. Designed for clinics needing real-time data transfer and remote ECG access for rapid diagnosis of heart conditions.
- Bioheart Personal heart rhythm monitoring device providing truly continuous 24/7 recording with 3 heart views (3 true or 12 derived), designed for lifestyle management and personal heart health tracking without requiring a prescription. Sold through shop.bioheart.com for individual consumers.
- Biokit FDA-cleared remote patient monitoring kit including pulse oximeter, blood pressure cuff, and digital thermometer for measuring temperature, blood pressure, and blood oxygen levels. Compatible with iOS and Android devices, designed for chronic disease management and telehealth integration.
- Biocare Holistic heart disease management platform combining chronic care management, remote patient monitoring, cardiac diagnostics, lifestyle management, bi-directional communication, and telemedicine into a single cloud-based portal that gives physicians a 360-degree view of patient heart health.
- HeartSecure At-home cardiac monitoring service providing a 10-day comprehensive heart analysis for $149-$199, including device, prepaid return shipping, expert cardiologist review, and detailed heart health report delivered within 72 hours. Available directly to individuals without a prescription.
Quantifiable outcome
- 3-5 day report turnaround vs 2+ weeks industry standard
- +3 more outcomes
Companies that use Biotricity
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Biotricity technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature6 records
Biotricity partnerships and signals
Strategic signalScale indicators8 records
Recent moves7 records
Expansion highlights6 records
Biotricity competitors and assessment
Company assessmentEmerging players
- Eko Health: Emerging player combining digital stethoscopes with AI-powered ECG analysis (CORE 500) for clinicians. Comparable in bringing consumer-grade form factors and AI diagnostics into the cardiac monitoring workflow that Biotricity targets with Biocore/Biocare.
- HeartBeam: Early-stage cardiac diagnostics company developing a credit-card-sized 3D ECG device for synthesized 12-lead readings. Comparable as a small-cap remote cardiac monitoring innovator targeting the same cardiology and at-home patient segments as Biotricity.
Direct peers
- AliveCor: Competes with Biotricity's Bioheart in consumer/DTC ECG monitoring (KardiaMobile and KardiaMobile 6L). Overlapping target customers (health-conscious individuals, AFib patients) with both prescription and non-prescription channels, and similar dual B2B/B2C go-to-market.
- iRhythm Technologies: Direct competitor in ambulatory cardiac monitoring with the Zio long-term continuous ECG patch service. iRhythm competes head-to-head with Biotricity's Biocore/Biocore Pro for cardiology clinic and electrophysiologist prescriptions using a similar reimbursement-driven GTM.
- Preventice Solutions (Boston Scientific): Was a direct competitor in mobile cardiac telemetry and Holter monitoring (BodyGuardian) before being acquired by Boston Scientific. Highly comparable product portfolio, customer base (cardiologists), and remote cardiac monitoring business model.
Broad incumbents
- Medtronic: Large incumbent in cardiac diagnostics, implantable loop recorders (LINQ), and remote monitoring (CareLink). Overlaps with Biotricity in cardiology diagnostics and remote patient monitoring but operates a much broader cardiovascular device portfolio at scale.
- GE HealthCare: Incumbent in hospital patient monitoring and ECG diagnostics with MUSE cardiology information systems. Comparable as a cardiac monitoring infrastructure vendor competing for the same clinician and health-system budgets as Biotricity, but with a much broader diagnostic imaging portfolio.
- Philips (Cardiac Monitoring): Broad incumbent offering legacy Holter, event monitoring, and centralized cardiac telemetry services through its Patient Monitoring business. Competes with Biotricity for hospital and cardiology clinic remote cardiac monitoring spend as part of a much wider medtech portfolio.
- Welch Allyn / Baxter (Hillrom): Incumbent in vital signs monitoring (BP, SpO2, temperature) comparable to Biotricity's Biokit, with broader ambulatory and bedside patient monitoring offerings distributed into physician offices and hospitals globally.
- Abbott: Incumbent with insertable cardiac monitors (Confirm Rx, Jot Dx) and a Connected Health remote monitoring platform. Directly overlaps Biotricity's cardiac monitoring franchise with implantable and external devices sold to electrophysiologists.
Market position
Strengths1 record
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Biotricity social profiles
Digital presenceBiotricity compliance and trust
Trust signalCompliance2 records
Biotricity financial estimates
Financial estimateRevenue estimate
Valuation estimate
Biotricity leadership team
Management profileNumber of profiles
Profiles9 records
Biotricity funding detail
Funding detailFunding overview
Funding rounds6 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Biotricity M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Biotricity
What does Biotricity do?
Biotricity designs, manufactures, and sells FDA-cleared remote cardiac monitoring hardware — including Bioflux, Biocore, Biocore Pro, Bioheart, and Biokit — that capture continuous ECG and vital-sign data via built-in cellular and Bluetooth connectivity and feed it to physicians through the proprietary Biocare cloud platform. Its offerings support arrhythmia detection, Holter monitoring, remote patient monitoring, chronic cardiac disease management, and direct-to-consumer at-home heart analysis (HeartSecure) for both clinical and personal use.
Is Biotricity a public or private company?
Biotricity is a public company. It is classified as public and is currently operating.
When was Biotricity founded?
Biotricity was founded in 2015. It employs 51 to 100 people.
Where is Biotricity based?
Biotricity is headquartered in Redwood City, United States, in the North America region.
How does Biotricity make money?
Four revenue lines are on record. Device/Hardware Sales are the primary driver. The others are subscription/Recurring Revenue, insurance Reimbursement and heartSecure Program.
Who are Biotricity's main competitors?
Emerging players on record are Eko Health and HeartBeam. Direct peers are AliveCor, iRhythm Technologies and Preventice Solutions (Boston Scientific). Broad incumbents are Medtronic, GE HealthCare, Philips (Cardiac Monitoring), Welch Allyn / Baxter (Hillrom) and Abbott.
Does Biotricity have an API?
No public API is recorded for Biotricity.
What industry is Biotricity in?
Biotricity's product category is Remote cardiac monitoring devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLACAPAB, Connected Medical Devices & Wearables (Sensors, Patches, Implantables). Its NAICS code is 334510 and its SIC code is 3845.